Compare $CBIO vs $NGNE | Chartloom

Compare

$CBIO vs $NGNE

Crescent Biopharma Inc · Neurogene Inc

CBIO

Crescent Biopharma Inc

NGNE

Neurogene Inc

Compare $CBIO vs $NGNE

Comparing Crescent Biopharma Inc and Neurogene Inc

CBIOCrescent Biopharma Inc

NGNENeurogene Inc

CBIOCrescent Biopharma Inc

Market cap

$532M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

34.6%

52W performance

23.6%

FCF yield

-28.9%

NGNENeurogene Inc

Market cap

$521M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

31.0%

52W performance

2.2%

FCF yield

-16.8%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

CBIO

NGNE

Detailed metrics comparison

CBIO

Crescent Biopharma Inc

NGNE

Neurogene Inc

Market Cap

CBIO$532M

NGNE$521M

Enterprise Value

CBIO$360M

NGNE$409M

Price

CBIO$14.91

NGNE$26.40

P/E Ratio

CBION/A

NGNEN/A

P/S Ratio

CBIO44.76x

NGNE0.00x

EV/Sales

CBIO30.32x

NGNE0.00x

EV/EBITDA

CBIO0.00x

NGNE0.00x

P/B Ratio

CBIO3.26x

NGNE2.36x

P/FCF Ratio

CBION/A

NGNEN/A

EV/FCF

CBIO-2.35x

NGNE-4.66x

PEG Ratio

CBION/A

NGNEN/A

Forward P/E (NTM)

CBION/A

NGNEN/A

Forward P/S (NTM)

CBION/A

NGNEN/A

Revenue (TTM)

CBIO$12M

NGNE$0

Revenue Growth (YoY)

CBION/A

NGNEN/A

Forward Rev Growth

CBIO-15.7%

NGNE127.3%

Gross Margin (TTM)

CBIO0.0%

NGNE0.0%

Operating Margin (TTM)

CBIO0.0%

NGNE0.0%

EBITDA Margin (TTM)

CBIO-1355.3%

NGNE0.0%

Net Margin (TTM)

CBIO-1406.4%

NGNE0.0%

FCF Margin (TTM)

CBIO-1292.8%

NGNEN/A

Net Income (TTM)

CBIO$-167M

NGNE$-46M

FCF (TTM)

CBIO$-154M

NGNE$-88M

EPS (TTM)

CBIO-$5.47

NGNE$0.00

ROE (TTM)

CBIO-10026.0%

NGNE-2527.0%

ROA (TTM)

CBIO-8791.0%

NGNE-2325.0%

ROIC (TTM)

CBIO-10026.0%

NGNE-2527.0%

Cash

CBIO$172M

NGNE$112M

Debt

CBIO$0

NGNE$8K

Net Cash/Debt

CBIO$172M

NGNE$112M

Current Ratio (TTM)

CBIO9.66x

NGNE10.64x

Quick Ratio (TTM)

CBIO9.26x

NGNE10.53x

Debt/Equity (TTM)

CBIO0.00x

NGNE0.00x

Debt/Assets (TTM)

CBIO0.0%

NGNE0.0%

Interest Coverage (TTM)

CBION/A

NGNEN/A

Net Debt/EBITDA (TTM)

CBIO0.00x

NGNE0.00x

Beta

CBIO1.39

NGNE1.71

52W Performance

CBIO23.6%

NGNE2.2%

YTD Performance

CBIO34.6%

NGNE31.0%

% from 52W High

CBIO-45.6%

NGNE-39.5%

% from 52W Low

CBIO71.0%

NGNE65.7%

Asset Turnover (TTM)

CBIO0.05x

NGNE0.00x

FCF Yield (TTM)

CBIO-28.9%

NGNE-16.8%

Earnings Yield (TTM)

CBIO-31.4%

NGNE-8.8%

Dividend Yield (TTM)

CBION/A

NGNEN/A

Rule of 40

CBIO-1,292.8

NGNE0.0

EV/GP/RG

CBION/A

NGNEN/A

Ticker research

View CBIO research View NGNE research

Metric	CBIO Crescent Biopharma Inc	NGNE Neurogene Inc
Market & Valuation
Market Cap	$532M	$521M
Enterprise Value	$360M	$409M
Price	$14.91	$26.40
P/E Ratio	N/A	N/A
P/S Ratio	44.76x	0.00x
EV/Sales	30.32x	0.00x
EV/EBITDA	0.00x	0.00x
P/B Ratio	3.26x	2.36x
P/FCF Ratio	N/A	N/A
EV/FCF	-2.35x	-4.66x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	N/A
Revenue & Growth
Revenue (TTM)	$12M	$0
Revenue Growth (YoY)	N/A	N/A
Forward Rev Growth	-15.7%	127.3%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-1355.3%	0.0%
Net Margin (TTM)	-1406.4%	0.0%
FCF Margin (TTM)	-1292.8%	N/A
Net Income (TTM)	$-167M	$-46M
FCF (TTM)	$-154M	$-88M
EPS (TTM)	-$5.47	$0.00
ROE (TTM)	-10026.0%	-2527.0%
ROA (TTM)	-8791.0%	-2325.0%
ROIC (TTM)	-10026.0%	-2527.0%
Financial Health
Cash	$172M	$112M
Debt	$0	$8K
Net Cash/Debt	$172M	$112M
Current Ratio (TTM)	9.66x	10.64x
Quick Ratio (TTM)	9.26x	10.53x
Debt/Equity (TTM)	0.00x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	1.39	1.71
52W Performance	23.6%	2.2%
YTD Performance	34.6%	31.0%
% from 52W High	-45.6%	-39.5%
% from 52W Low	71.0%	65.7%
Efficiency & Yields
Asset Turnover (TTM)	0.05x	0.00x
FCF Yield (TTM)	-28.9%	-16.8%
Earnings Yield (TTM)	-31.4%	-8.8%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-1,292.8	0.0
EV/GP/RG	N/A	N/A
Ticker research	View CBIO research	View NGNE research

Valuation

P/S Ratio

NGNE

0.00x

CBIO

44.76x

EV/FCF

NGNE

-4.66x

CBIO

-2.35x

Growth & revenue

Forward Revenue Growth

NGNE

127.3%

CBIO

-15.7%

Profitability & performance

Gross Margin

CBIO

0.0%

NGNE

0.0%

ROE

NGNE

-2527.0%

CBIO

-10026.0%

FCF Yield %

NGNE

-16.8%

CBIO

-28.9%

52-Week Performance

CBIO

23.6%

NGNE

2.2%

Detailed metrics comparison

CBIO

Crescent Biopharma Inc

NGNE

Neurogene Inc

Market Cap

CBIO$532M

NGNE$521M

Enterprise Value

CBIO$360M

NGNE$409M

Price

CBIO$14.91

NGNE$26.40

P/E Ratio

CBION/A

NGNEN/A

P/S Ratio

CBIO44.76x

NGNE0.00x

EV/Sales

CBIO30.32x

NGNE0.00x

EV/EBITDA

CBIO0.00x

NGNE0.00x

P/B Ratio

CBIO3.26x

NGNE2.36x

P/FCF Ratio

CBION/A

NGNEN/A

EV/FCF

CBIO-2.35x

NGNE-4.66x

PEG Ratio

CBION/A

NGNEN/A

Forward P/E (NTM)

CBION/A

NGNEN/A

Forward P/S (NTM)

CBION/A

NGNEN/A

Revenue (TTM)

CBIO$12M

NGNE$0

Revenue Growth (YoY)

CBION/A

NGNEN/A

Forward Rev Growth

CBIO-15.7%

NGNE127.3%

Gross Margin (TTM)

CBIO0.0%

NGNE0.0%

Operating Margin (TTM)

CBIO0.0%

NGNE0.0%

EBITDA Margin (TTM)

CBIO-1355.3%

NGNE0.0%

Net Margin (TTM)

CBIO-1406.4%

NGNE0.0%

FCF Margin (TTM)

CBIO-1292.8%

NGNEN/A

Net Income (TTM)

CBIO$-167M

NGNE$-46M

FCF (TTM)

CBIO$-154M

NGNE$-88M

EPS (TTM)

CBIO-$5.47

NGNE$0.00

ROE (TTM)

CBIO-10026.0%

NGNE-2527.0%

ROA (TTM)

CBIO-8791.0%

NGNE-2325.0%

ROIC (TTM)

CBIO-10026.0%

NGNE-2527.0%

Cash

CBIO$172M

NGNE$112M

Debt

CBIO$0

NGNE$8K

Net Cash/Debt

CBIO$172M

NGNE$112M

Current Ratio (TTM)

CBIO9.66x

NGNE10.64x

Quick Ratio (TTM)

CBIO9.26x

NGNE10.53x

Debt/Equity (TTM)

CBIO0.00x

NGNE0.00x

Debt/Assets (TTM)

CBIO0.0%

NGNE0.0%

Interest Coverage (TTM)

CBION/A

NGNEN/A

Net Debt/EBITDA (TTM)

CBIO0.00x

NGNE0.00x

Beta

CBIO1.39

NGNE1.71

52W Performance

CBIO23.6%

NGNE2.2%

YTD Performance

CBIO34.6%

NGNE31.0%

% from 52W High

CBIO-45.6%

NGNE-39.5%

% from 52W Low

CBIO71.0%

NGNE65.7%

Asset Turnover (TTM)

CBIO0.05x

NGNE0.00x

FCF Yield (TTM)

CBIO-28.9%

NGNE-16.8%

Earnings Yield (TTM)

CBIO-31.4%

NGNE-8.8%

Dividend Yield (TTM)

CBION/A

NGNEN/A

Rule of 40

CBIO-1,292.8

NGNE0.0

EV/GP/RG

CBION/A

NGNEN/A

Ticker research

View CBIO research View NGNE research

Metric	CBIO Crescent Biopharma Inc	NGNE Neurogene Inc
Market & Valuation
Market Cap	$532M	$521M
Enterprise Value	$360M	$409M
Price	$14.91	$26.40
P/E Ratio	N/A	N/A
P/S Ratio	44.76x	0.00x
EV/Sales	30.32x	0.00x
EV/EBITDA	0.00x	0.00x
P/B Ratio	3.26x	2.36x
P/FCF Ratio	N/A	N/A
EV/FCF	-2.35x	-4.66x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	N/A
Revenue & Growth
Revenue (TTM)	$12M	$0
Revenue Growth (YoY)	N/A	N/A
Forward Rev Growth	-15.7%	127.3%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-1355.3%	0.0%
Net Margin (TTM)	-1406.4%	0.0%
FCF Margin (TTM)	-1292.8%	N/A
Net Income (TTM)	$-167M	$-46M
FCF (TTM)	$-154M	$-88M
EPS (TTM)	-$5.47	$0.00
ROE (TTM)	-10026.0%	-2527.0%
ROA (TTM)	-8791.0%	-2325.0%
ROIC (TTM)	-10026.0%	-2527.0%
Financial Health
Cash	$172M	$112M
Debt	$0	$8K
Net Cash/Debt	$172M	$112M
Current Ratio (TTM)	9.66x	10.64x
Quick Ratio (TTM)	9.26x	10.53x
Debt/Equity (TTM)	0.00x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	1.39	1.71
52W Performance	23.6%	2.2%
YTD Performance	34.6%	31.0%
% from 52W High	-45.6%	-39.5%
% from 52W Low	71.0%	65.7%
Efficiency & Yields
Asset Turnover (TTM)	0.05x	0.00x
FCF Yield (TTM)	-28.9%	-16.8%
Earnings Yield (TTM)	-31.4%	-8.8%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-1,292.8	0.0
EV/GP/RG	N/A	N/A
Ticker research	View CBIO research	View NGNE research